With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.

BIO's about-face in its relationship with WuXi AppTec illustrates the difficulty the biotech industry faces in dealing with an issue that is moving fast and forcefully.

Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.

New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…

Medicare estimates a new Alzheimer’s drug could cost the program billions of dollars by next year — well beyond what Wall Street or the drug’s manufacturer project.

Is there any circumstance when a 486% increase for a medicine might be justified? A small company called Harrow argues the case for an injectable eye treatment.

Abortion opponents often say they want to support survivors of rape. But abortion bans do the opposite, and no fake "rape exception" is going to change that.

Biotech startups recently closed out their best fundraising quarter in two years, signaling that the industry downturn may soon be a thing of the past.

HCA Healthcare, the country's biggest hospital chain, reported almost $1 billion more in charity care to CMS than in its financial statement, drawing more taxpayer money.

Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Boehringer Ingelheim will lay off an undisclosed number of sales reps due to poor U.S. sales of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira.

Advisers to the Nuclear Regulatory Commission, a U.S. government agency tasked with ensuring the safe use of radioactive materials, were beset by conflicts of interest, report finds

Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and Canada, ending a multi-year saga for patients with the rare neurodegenerative disease.

A White House plan to stem drug shortages involves basing Medicare payments on whether hospitals adopt business practices that avoid shortages.

Top European prosecutors are investigating allegations of criminal wrongdoing in connection with the European Commission president's vaccine negotiations with Pfizer.

AstraZeneca’s plan to pay CEO Pascal Soriot up to £18.7 million has been branded “excessive” by two shareholder advisers.

The first major U.S. health insurers have agreed to start paying for the Wegovy weight loss drug for certain people on Medicare with heart conditions.

A new study links GLP-1 drugs like Ozempic to a higher risk of aspiration pneumonia — a lung infection caused by food breathed into the lungs — after endoscopies.

The Stanford lab of Irv Weissman channeled its cancer-targeting expertise to tip the immune systems of aged mice back to a youthful state.

U.S. Supreme Court justices focused on plaintiffs' right to sue the FDA to reinstate restrictions on a commonly used abortion pill, suggesting they are unlikely to restrict access.

AstraZeneca filed a lawsuit seeking to block an Arkansas law that requires the company to ship its medicines to any pharmacy working with hospitals participating in a federal discount program.

Amgen accused a Colorado board of violating the U.S. Constitution with its first-in-the-nation plan to cap the cost of a pricey prescription medicine.

While access to donor hearts has increased, there are still gender- and race-based disparities in the acceptance rate of a donor heart offer by transplant teams, a new study finds.

Novo Nordisk agreed to acquire Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional cardiometabolic drug candidates.

This morning in the Pharmalittle roundup: We're reading about Medicare and obesity drugs, FDA syringe warnings, and more.

When it comes to device makers, regulators and payers should be on the lookout for Uber-like behavior — including aggressive marketing strategies.

Researchers and government agencies in the U.K. are trying to figure out how to best advance individualized genetic treatments.

The Congressional Budget Office forecast that Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years.”